Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Impact · against what's priced in

Annexon's reporting of rapid, positive clinical outcomes in the GBS FORWARD study for Tanruprubart provides material evidence of treatment reproducibility, increasing the probability of FDA approval. The upcoming JPM Healthcare Conference presentation serves as a secondary catalyst for investor visibility.

ANNX+0.60

No priced-in read yet